Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision metadata was updated from v3.6.4 to v3.6.5, indicating a minor update to the page.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s revision tag was updated to a newer version, indicating a small update to the study record’s metadata. This does not modify the study details or visible content.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now shows a new revision number (v3.6.3) replacing the previous v3.6.2, indicating a page update. This update does not alter study content or eligibility criteria.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, signaling a newer build/version of the page. This reflects an update to the page infrastructure rather than alterations to study content.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page now displays 'No longer looking for participants' and standardizes the header to Intervention/Treatment, signaling that recruitment has closed. The page revision was updated to v3.6.0 and new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) were added.SummaryDifference0.2%

- Check82 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5, reflecting a new release version displayed on the page. The update is administrative and does not change study data, eligibility criteria, or how users interact with the page.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.